Opdivo (nivolumab)

pCPA File Number: 22721
Negotiation Status:
Active Negotiation
Indication(s):
​Opdivo, as monotherapy, is indicated for the adjuvant treatment of adult patients with Stage IIB or IIC melanoma following complete resection.
Sponsor/Manufacturer:
Bristol Myers Squibb Canada Inc.
CDA-AMC Project Number:
PC0339-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable